RecruitingPHASE1, PHASE2NCT04390737

Evaluate the Safety and Clinical Activity of HH2853

Studying Epithelioid sarcoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Haihe Biopharma Co., Ltd.
Principal Investigator: Fugen Li
Haihe Biopharma Co., Ltd.
Intervention: HH2853 Tablets(drug)
Enrollment: 254 target
Eligibility: 18 years · All sexes
Timeline: 2020 – 2028

Study locations (24)

Mayo Clinic, Phoenix, Arizona, United States
Mayo Clinic, Jacksonville, Florida, United States
Mayo Clinic, Rochester, Minnesota, United States
NEXT Oncology, San Antonio, Texas, United States
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Beijing Jishuitan Hospital, Beijing, Beijing Municipality, China
Sun Yat-Sen University Cancer Hospital, Guangzhou, Guangdong, China
Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China
Liaoning Cancer Hospital&Institute, Shenyang, Liaoning, China
Shengjing Hospital Of China Medical University, Shenyang, Liaoning, China
+9 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04390737 on ClinicalTrials.gov

Other trials for Epithelioid sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Epithelioid sarcoma →

← Back to all trials